AGM summary BATM AGM 18/10/2017Just my impressions so make your own decisions. I will address the options issue first. This was rejected. There was a debate around this and the debate was wide ranging. The UK is currently scrutinisng executive salaries more and I asked had they discussed it with the institutions before making the resolution and what was the support for that. The answer was 75% for and 25% against. As a very small player I have to respect the views of the institutions. The CFO had discussed it with the institutions and also KPMG. The option were set at the current SP and activated after 24 and 36 months. I suggested that I fully supported options but why not action them at a higher SP when targets have been achieved. Dr Zvi Marom then replied and said he feels that it is easy to get an SP up by selling valuable assets/intellectual property and people are tempted to take the short term approach rather than grow the business and let the SP look after itself. The company has no debt; has not come back to shareholders for funds; the salaries of staff is low by international comparisons and he has not taken a pay rise in 12 years. He travels economy; does not have a car allowance and wants the team to have genuine performance parameters rather than the machinations of playing the SP. All R and D is carried out from revenue and has never been capitalised. All excellent points imo. The fact that most staff are in Israel rather than the UK or the US is another factor. I am sure this issue will be resolved and I felt it was a useful discussion. It will take him from 23% to 24% which is not a lot in the scheme of things and the company has been his baby.Xvi then went into his summary of events and started with 2007! The mobile phone was a phone and little else. It was hardware driven. With the introduction of the smartphone-in 2007 the world changed. The smartphone is a computer with a phone app. The software is the key not the hardware and the process is customer centric not network centric. BATM has been developing its telco side along these lines while companies like Nortel and others have fallen by the wayside. BATM has at least survived! The recent RNS talking about the collaboration with ARM is an example of that. They have been working together for a year and their software on the ARM processor means that software can function on any hardware. Not Intel centric on Intel or ARM centric on ARM. This app allows any software on either processor. ARM is more cyber secure than Intel but less software can run on it. Intel is less cyber secure but can run more software options. BATM is now in discussion with both after the Exhibition in Amsterdam last week.The second element to all this is cybersecurity. It is a strategic issue not just a defence issue. Cyber attacks are the new Bonnie and Clyde. The software sits on the junctions of the company/countrys networks. The parameters are then adapted to the needs of the particular organisation and the systems are all monitored. It is a cyber Interpol concept. Thy have had a range of Proof of Concept (POC) trials running. They have signed a major project for this recently with a government. They have just won a POC contract for which the potential purchaser is paying them -$350K -to do this and from that a contract may follow-another government-European-it takes about 9 months from POC to contract. I certainly came away with the impression that Dr Marom was pleased with the way this aspect of the business was developing. Most of the available time was spent on this as opposed to the Bio Medical side of things. Having said that he explained the development of that aspect by explaining how they started in the distribution side of products and then moved to the services side of things with the focus on genomics. This has resulted in AMUR-the Diagnostics side and is all about molecular biology. The plan is to supply equipment and the test kits to 10 internation
Re: RNS yes-I will expand in my AGM summary which was a well spent 2 and a half hour session-to follow asap-in the next 24 hours!
RNS I've just noted that the proposed options were not agreed. Have I read the RNS correctly?
no impact from today's news Announcement this morning has yielded a trading volume of 98,000.BATM is a master at issuing "no impact" news. Today we have another one.The news release should give an indication of the commercial benefit ie how it will increase revenue and profit. The reason being it will have no impact whatsoever."BATM Advanced Communications' wholly-owned subsidiary, Telco Systems, together with NXP Semiconductors have launched the industry's first and only Arm-based uCPE networking technology solution.BATM said this utilises the group's NFVTime plug-and-play solution that enables network function virtualisation.It said that as a result, the group's NFV and software-defined network solutions, which were already integrated with Intel-based platforms, were now available on all major architectures.It added: 'The new solution, which is commercially available, was developed by Telco and NXP, in close collaboration with Arm.'Telco has become an Arm ecosystem partner - and is the only such partner to enable NFV infrastructure.'The group said it expected to receive initial sales from the new platform in 2017."
Tumbleweed Drifting along with a tumbling tumbleweed
high volume today over 2 m shares traded so far today, following the news of the order in the US. Despite the increased level of trading the price is sticking around 18p.
Re: Another year of failure I'm sitting on a loss which is why I'm not selling. I bought several years ago in the high 20s and have have heard all this "jam tomorrow" every year. When it fell to 12/13p those who bought will be happy but not me. Marom is a nice chap but he is not a CEO. He has a massive holding in the company and I've been told he has to go through many hoops to buy shares so he totally believes in the company. This in itself is, in my view, the root of the company's problem. Its his baby and he can't make the hard decisions needed to move the company from being an R&D organisation to a commercial profitable business. The only way this company will grow is if Marom stands aside and lets a new management team take the reins and drive it as a business not as academic research organisation.I've kept the shares in the belief that it will be taken over but because it now has 2 unrelated business groups its hard to see who would buy. When it was just telco it looked possible but with the pharma/waste unit and the telco its more complicated. Fans of the company always roll out the view as articulated by the IC, but the share price never takes off. I spoke to a fund manager 2/3 years ago who has a significant holding and he persuaded me things would happen so I held on but nothing has changed. I attended an AGM a few years ago and Marom promised me things would improve. At the time the price was 20p and no dividend. I'm a simple chap I buy shares to make a profit. This share is a dog.Good luck
Re: Another year of failure before you get too critical you should read the Simon Thompson column in the IC today-he takes a much more positive angle to the business and also had a conversation with the CEO today to expand further on the results. He also recommends them as a strong buy. If you do not like the management or the results why not sell up and buy into something else. I hope to be at the AGM as well and hope you can be constructive in your comments and informed before you have a go at them. The mobile agri-waste machine should be the first of many; the new Integrated shredder and sterilizer units will be delivered to 3 hospitals in the US this year to another untapped market; the Egens 5% in Adaltis values the business @ $58m when BATM holds 95%. BATM is valued @£72m of which cash is £12m and property assets £15.6m. The JV with Ador has 40 patents for medical diagnostics. Of the £2m operating loss only £400k is cash -the rest is depreciation and amortization. On the cyber side he hopes for more contracts in the 2nd half from all the POCs thye are involve in at present. Expected revenue is $46.3m and PTP $2.3m so let's hope things will turn out for the 2nd half. Basically the SP reflects the value of the hard assets and Adaltis and the rest are in there for zilch-maybe the market has got it wrong-not the management. Just my view. I was at the 2106 AGM and was impressed by the expertise on the Board covering all the areas in which they were involved and the latest management appointment reflects that the relevant expertise is covering the range of areas.
Another year of failure How does Marom get away with his year after year failure. Operating loss increased by $1m!!Revenue increased by $4m and he lost $1m.As I've been saying for years on this board. his cost base is inappropriate for such a small company. He needs to take out cost and focus on one business - how can such a small business expect to improve shareholder value with 2 very diverse business units.He needs to be replaced now along with his management team. I will definitely go to the AGM this year and vent my feelings
Shore capital exclusive adviser They have reduced their financial advisers down to 1 - Shore Capital. I my view it would have made sense to get rid of Shore and get a brand new adviser who could put a fresh pair of eyes on the dysfunctional BATM. Shore has been there for years. The cosy relationships continues.
BATM appoints CEO at subsidiary Adaltis BATM appoints CEO at subsidiary Adaltis08:42 03 Jul 2017This is a new role created within Adaltis as it gears up to take advantage of the advances made within its molecular biology business unitDiagnostic equipmentAdaltis is a majority-owned subsidiary of BATM that manufactures medical diagnostic equipment.BATM Advanced Communications Ltd (LON:BVC) has appointed medtech industry veteran Dr David Perry as chief executive officer of its subsidiary, Adaltis.As part of the restructuring of the senior team, the board of Adaltis is promoting the current general manager, Marco Spadaciolli, to chief operating officer.Dr Perry has more than 20 years' international experience in developing and bringing to global markets new medical devices, and pharmaceutical and biotechnological products across multiple therapy areas, and in small and large companies. Most recently he served as principal of Lilium Bioscience, a company dedicated to bringing to market novel therapeutic and medical-device products in the areas of biosurgery, orthopaedics, regenerative medicine and dermatology."We are delighted to have David join Adaltis. We believe that Adaltis is maturing to be an important player in the in-vitro diagnostic field and is making the necessary steps to achieve that. We look forward to leveraging David's experience as we take Adaltis to the next stage of its development, said Dr Zvi Marom, chief executive officer of BATM.From the Proactive Investors site.[link]
Annual report I've just read the annual report. Its amazing how every year BATM churns out an upbeat statement about how it is positioned for growth and growth never happens. Zvi earns $399k per year and owns 96m shares approx 25% of the total shares and over the last 10 years has achieved very little. The medical division is the so called growth engine of the company. I'll believe it when I see it.For such a small company $90m revenue it should be delivering much higher profits and running a much smaller cost base.I also spotted that Zvi is a paid director of Shore Capital (one of BATM's financial advisers and stock brokers) That can't be right - conflict of interest?
is there some positive news on the way sp up today Is someone about to buy BATM. 230,000 trades today all buys very unusual
heading south again How many times have I seen this!!!Dr Marom please stand aside so i can at least get my money back by letting someone take it over
Re: Same old I should sell but I'm convinced someone will buy it and relieve Marom of his responsibilities.Ever hopefull I've held for more than 5 years paid about 26p a long time ago